On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major ...

Johnson & Johnson's Spravato therapy for treatment ... the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from ...

Johnson & Johnson has priced its new Spravato ... has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value threshold.

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Johnson & Johnson (NYSE:JNJ) is advancing psychedelic medicine with Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression and acute suicidal ideation. Since its ...

Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa ...

Johnson & Johnson (NYSE:JNJ) is advancing psychedelic medicine with Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression and acute suicidal ideation. Since its ...

In 2024, Johnson & Johnson acquired Shockwave Medical for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.